SonaCare Medical Sells Prostate Ablation System with MRI/Ultrasound Image Fusion to Heidelberg Prostate Clinic
Charlotte, NC (PRWEB) July 08, 2015 -- SonaCare Medical, global leader in high-intensity focused ultrasound (HIFU) ablation devices, announced today the purchase of a newest generation Sonasource with Sonablate® prostate ablation probes by Klinik für Prostata Therapie (Clinic for Prostate Therapy) in Heidelberg, Germany. SonaCare’s Germany-based distribution partner Dr. Sennewald Medizintechnik GmbH facilitated the purchase and will collaborate with the clinic and SonaCare to form a German HIFU and Focal Therapy demonstration center in Heidelberg.
Klinik für Prostata Therapie customized their system with Sonafuse Profuse, which fuses a previously obtained magnetic resonance image with live ultrasound during the HIFU procedure. This allows the visualization of regions of abnormality visible with MRI but not normally visible with ultrasound during the procedure for targeted treatment. The fusion program is based on Artemis Profuse software from Eigen, one of three SonaCare Medical fusion partners that provide seamless integration with physicians’ targeted biopsy systems.
Specializing in minimally-invasive, multimodal prostate cancer therapy, Klinik für Prostata Therapie has been using an older model of Sonablate for prostate ablation. According to Dr. Thomas Dill, partner and urologist at Klinik für Prostata Therapie, “We pride ourselves in combining a pleasant, patient-centered atmosphere with the most modern medical technology. Upgrading to the most advanced prostate HIFU device just made sense. We have treated over 500 patients with Sonablate and we feel that HIFU, especially focal therapy, is the ideal fit for our clinic.”
Dr. Martin Löhr, also partner and urologist at the clinic, comments, “As the first clinic in Germany to have implemented minimally invasive methods to treat prostate cancer, we are looking forward to continuing on our mission to make prostate cancer treatment in Germany and all of Europe gentler and more disease, instead of whole gland, focused. For the appropriate patient group focal therapy has shown effective cancer control with a minimal side effect profile. We are looking forward to welcoming physicians into our clinic and training them on Sonablate HIFU.”
Together with SonaCare Medical’s distributor Dr. Sennewald Medizintechnik, the clinic will establish a HIFU demonstration center that will serve physicians from Germany and central Europe.
“Gaining highly experienced users like Dr. Löhr and Dr. Dill as coaches for physicians interested in learning about therapeutic ultrasound and focal therapy is excellent news for the Company. Peer-to-peer communication is essential in our quest to making minimally-invasive prostate therapy options accessible to men world-wide” says Dr. Mark Carol, CEO at SonaCare Medical.
About SonaCare Medical
SonaCare Medical, a privately held, venture-backed healthcare company is a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies. SonaCare Medical is committed to developing technologies for urological indications that offer precise and innovative procedures that can control cancer and reduce potential quality of life altering side effects. SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs and manufactures high intensity focused ultrasound (HIFU) medical devices, including the following: Sonablate® 450 which is investigational in the U.S. and being studied in a pivotal FDA clinical trial as a possible treatment for recurrent prostate cancer in patients treated previously with external beam radiation therapy; Sonablate® 500, which has CE Marking and is, or has been, approved for use to treat prostate cancer in more than 49 countries outside the U.S. and is pending De Novo submission review by the FDA; and Sonatherm® laparoscopic HIFU surgical ablation system which is 510(k) cleared in the U.S., has CE Marking and is approved in more than 30 countries outside the U.S. The FDA has made no decision as to the safety or efficacy of Sonablate® 450 or 500. In the event the Sonablate® 500 De Novo is granted or Sonablate® 450 is approved by the FDA for use in the U.S., there is no assurance that instructions for use or the specifications of the device will be the same for treatment approved or authorized in other countries outside of the U.S. SonaCare Medical was founded in 2004 and is headquartered in Charlotte, N.C.
For additional information, visit http://www.SonaCareMedical.com
Sandra Stein, SonaCare Medical, http://www.sonacaremedical.com, +1 7048171167, [email protected]
Share this article